Clinical Trials Logo

Esophageal Cancer Stage III clinical trials

View clinical trials related to Esophageal Cancer Stage III.

Filter by:
  • None
  • Page 1

NCT ID: NCT03366883 Not yet recruiting - Clinical trials for Esophageal Cancer Stage III

Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC

Start date: February 1, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III clinical trail which Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy with Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer. The Preoperative chemoradiotherapy with radical surgery is the standard treatment in China. But, many patients do not receive this treatment for many other reasons. Most of them refused or abandon radiotherapy because of the Intolerable adverse effects of radiotherapy, so we have launched a randomized controlled trial to confirm the non-inferiority of TCF over chemoradiotherapy with TC (TC-RT) as preoperative therapy for locally advanced esophageal squamous cancer in overall survival.

NCT ID: NCT03087864 Completed - Clinical trials for Esophageal Cancer Stage III

PDL-1 Targeting in Resectable Oesophageal Cancer

PERFECT
Start date: June 28, 2017
Phase: Phase 2
Study type: Interventional

Objectives The primary objective of this study is to assess the feasibility of preoperative treatment with atezolizumab combined with preoperative chemoradiation (carboplatin, paclitaxel and radiation) in terms of completion of treatment with atezolizumab.

NCT ID: NCT00578201 Completed - Clinical trials for Esophageal Cancer Stage III

FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer

FOLFOX
Start date: November 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the effects of oxaliplatin, leucovorin and fluorouracil-when given together with Cetuximab and radiation therapy and radiation therapy to see how they work in treating patients with stage III esophageal cancer.